SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, today announced a settlement agreement with Duke University, Eisai, Inc. and Eisai Co., Ltd., collectively “Eisai,” related to a previously-settled lawsuit filed jointly by Orexigen and Duke to resolve a dispute over rights in an invention relating to the use of zonisamide to treat obesity. This settlement agreement, which resolves the foreign aspects of the parties’ dispute, follows an earlier settlement agreement executed in December 2006, which settled the U.S. aspects of the parties’ dispute.
